BridgeBio director granted 3,990 RSUs, options

BridgeBio Pharma director Ali J. Satvat reported equity awards rather than market trades.

Rhea-AI Filing Summary

BridgeBio Pharma director Ali J. Satvat reported equity awards rather than market trades. He received 3,990 restricted stock units (RSUs) that vest in full on June 22, 2027, conditioned on his continued service on the board. Each RSU represents a contingent right to receive one share of BridgeBio’s common stock.

Satvat was also granted a stock option covering 5,277 shares of common stock at an exercise price of $68.9200 per share, expiring on June 21, 2036. These option shares vest in full on June 22, 2027, subject to the same continued-service condition. Following the RSU grant, he directly holds 169,983 shares of common stock.

Insider Trade Summary

Grant/Award: 9,267 shares

Grant/Award 2 txns

Insider Satvat Ali J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,277	$0.00	$0.00
Grant/Award	Common Stock	3,990	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,277 contracts (Direct); Common Stock — 169,983 shares (Direct)

Footnotes (3)

1. F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. F3. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Key Figures

RSU grant: 3,990 RSUs Stock option grant size: 5,277 shares Option exercise price: $68.9200 per share +4 more

7 metrics

RSU grant 3,990 RSUs Award to director Ali J. Satvat, vesting June 22, 2027

Stock option grant size 5,277 shares Underlying common stock for new option award

Option exercise price $68.9200 per share Strike price for 5,277-share stock option

Option expiration June 21, 2036 Expiration date of new stock option grant

Option vesting date June 22, 2027 Full vesting date for option shares

RSU vesting date June 22, 2027 Full vesting date for 3,990 RSUs

Shares held after grant 169,983 shares Direct common stock holdings after RSU award

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan, vest in full, +1 more

5 terms

restricted stock units ("RSUs") financial

"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with 5,277.0000 shares at a $68.9200 exercise price."

2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan financial

"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."

vest in full financial

"The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service."

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BridgeBio Pharma (BBIO) director Ali J. Satvat report in this Form 4?

Ali J. Satvat reported receiving equity awards, not open-market trades. He was granted 3,990 restricted stock units and a stock option for 5,277 shares, both tied to future vesting based on continued board service.

How many restricted stock units did BBIO grant to director Ali J. Satvat?

BridgeBio granted Ali J. Satvat 3,990 restricted stock units. These RSUs vest in full on June 22, 2027, if he continues serving on the board, and each unit converts into one share of the company’s common stock at settlement.

What are the terms of Ali J. Satvat’s new BridgeBio stock option grant?

Satvat received a stock option covering 5,277 shares of common stock at an exercise price of $68.9200 per share. The option vests in full on June 22, 2027, subject to continued board service, and expires on June 21, 2036.

When do Ali J. Satvat’s BridgeBio RSUs and options vest?

Both the 3,990 RSUs and the stock option for 5,277 underlying shares vest in full on June 22, 2027. Vesting depends on Satvat’s continued service on BridgeBio’s board of directors through that date, according to the award terms.

How many BridgeBio common shares does Ali J. Satvat hold after these grants?

After the RSU grant, Satvat directly holds 169,983 shares of BridgeBio common stock. This figure reflects his reported direct ownership following the equity award and does not include unvested RSUs or unexercised option shares disclosed in the same filing.

What plan governs Ali J. Satvat’s new BridgeBio RSU award?

The RSU grant was issued under BridgeBio’s 2021 Amended and Restated Stock Option and Incentive Plan. This plan provides for equity-based compensation, and the RSUs vest in full on June 22, 2027, contingent on Satvat continuing to serve on the board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 06:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Satvat Ali J.

(Last) (First) (Middle)

C/O KOHLBERG KRAVIS ROBERTS & CO. L.P.

2800 SAND HILL ROAD

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		A(1)		3,990	A	$0(2)	169,983	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$68.92	06/22/2026		A		5,277		(3)	06/21/2036	Common Stock	5,277	$0	5,277	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Will Solis, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)